Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
Saved in:
| Title: | Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer. |
|---|---|
| Authors: | Cao J; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Zhu Z; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Wang H; Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA., Nichols TC; Drug Safety Research and Development, Pfizer Inc., San Diego, CA, 92121, USA., Lui GYL; Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA., Deng S; Biostatistics, La Jolla Laboratories, Pfizer Inc., San Diego, CA, 92121, USA., Rejto PA; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., VanArsdale T; Tumor Cell Biology, Oncology Research and Development, Pfizer Inc., San Diego, CA, 92121, USA., Hardwick JS; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Weinrich SL; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Wei P; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA. ping.wei@pfizer.com. |
| Source: | Oncogene [Oncogene] 2019 May; Vol. 38 (21), pp. 4125-4141. Date of Electronic Publication: 2019 Jan 30. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 30700828 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Cao+J%22">Cao J</searchLink>; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Zhu+Z%22">Zhu Z</searchLink>; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Wang+H%22">Wang H</searchLink>; Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Nichols+TC%22">Nichols TC</searchLink>; Drug Safety Research and Development, Pfizer Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Lui+GYL%22">Lui GYL</searchLink>; Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.<br /><searchLink fieldCode="AU" term="%22Deng+S%22">Deng S</searchLink>; Biostatistics, La Jolla Laboratories, Pfizer Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Rejto+PA%22">Rejto PA</searchLink>; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22VanArsdale+T%22">VanArsdale T</searchLink>; Tumor Cell Biology, Oncology Research and Development, Pfizer Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Hardwick+JS%22">Hardwick JS</searchLink>; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Weinrich+SL%22">Weinrich SL</searchLink>; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA.<br /><searchLink fieldCode="AU" term="%22Wei+P%22">Wei P</searchLink>; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA. ping.wei@pfizer.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228711562%22">Oncogene</searchLink> [Oncogene] 2019 May; Vol. 38 (21), pp. 4125-4141. <i>Date of Electronic Publication: </i>2019 Jan 30. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8711562 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1476-5594 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209509232%22">09509232 </searchLink><i>NLM ISO Abbreviation: </i>Oncogene <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=30700828 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41388-019-0708-7 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 4125 Titles: – TitleFull: Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Cao J – PersonEntity: Name: NameFull: Zhu Z – PersonEntity: Name: NameFull: Wang H – PersonEntity: Name: NameFull: Nichols TC – PersonEntity: Name: NameFull: Lui GYL – PersonEntity: Name: NameFull: Deng S – PersonEntity: Name: NameFull: Rejto PA – PersonEntity: Name: NameFull: VanArsdale T – PersonEntity: Name: NameFull: Hardwick JS – PersonEntity: Name: NameFull: Weinrich SL – PersonEntity: Name: NameFull: Wei P IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2019 May Type: published Y: 2019 Identifiers: – Type: issn-electronic Value: 1476-5594 Numbering: – Type: volume Value: 38 – Type: issue Value: 21 Titles: – TitleFull: Oncogene Type: main |
| ResultId | 1 |
